反応式
[CH2:1]1[CH2:5]O[CH2:3][CH2:2]1.[CH:6]1N=CN(C(N2C=[N:16][CH:15]=[CH:14]2)=O)[CH:7]=1.[ClH:18].N[CH2:20][CH2:21][C:22]1[C:30]2[C:25](=[CH:26][CH:27]=[CH:28][CH:29]=2)N[CH:23]=1.CCN(C(C)C)[CH:34]([CH3:36])[CH3:35]>CN(C=O)C>[CH3:3][C:2]1[CH:36]=[CH:34][C:35]([CH:15]([NH2:16])[C:14]2[CH:29]=[CH:30][CH:22]=[CH:21][CH:20]=2)=[CH:5][CH:1]=1.[CH2:21]=[CH:22][C:30]1[CH:25]=[CH:26][CH:27]=[CH:28][CH:29]=1.[CH2:6]=[CH:7][C:27]1[CH:28]=[CH:29][C:30]([CH:22]=[CH2:23])=[CH:25][CH:26]=1.[ClH:18]参加物
実験手順
Fmoc-Asn(Trt)Ser(But)PheAzaGlyLeuArg(Me,Boc2)Phe-Rink-Amide MBHA resin prepared in EXAMPLE 8 was subjected to Fmoc deprotection. To 64 mg (20 μmol) of H-Asn(Trt)Ser(But)PheAzaGlyLeuArg(Me,Boc2)Phe-Rink Amide MBHA resin, 1.5 mL of THF and 13 mg of CDI were added, followed by shaking for 2 hours. After 32 mg of tryptamine hydrochloride, 28 μL of DIEA and 500 μL of DMF were added to the mixture, followed by shaking for 24 hours. Thereafter the resin washed to give 2-(Indol-3-yl)ethylcarbamoyl-Asn(Trt)Ser(But)PheAzaGlyLeuArg(Me,Boc2)Phe-Rink Amied MBHA resin. To 15 mg of the product, 200 μL of TFA/PhSMe/m-cresol/TIS/EDT (85/5/5/2.5/2.5) was added, followed by stirring for 2 hours. Ether was added to the reaction solution, the resulting precipitate was centrifuged and the supernatant was removed. This procedure was repeated for washing. The residue was extracted with an aqueous acetic acid solution and the extract was filtered to remove the resin. Then, linear density gradient elution (60 minutes) was performed with eluants A/B: 69/31-59/41 using: 0.1% TFA in water and eluant B: 0.1% TFA-containing acetonitrile on preparative HPLC using YMC D-ODS-5-ST S-5 120A column (20×150 mm). The fractions containing the product were collected and lyophilized to give 1.1 mg of white powders.
後処理
- stirringby shaking for 24 hours
- washThereafter the resin washed
出典と根拠
- ORDレコード
- ord-347cc4cbfcce42d995500dc8466f8f94
- 出典データセット
- uspto-grants-2014_07
- 特許番号
- US08778871B2
関連ノート
読み込み中…